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TITLE :   
Curcumin exerts a chemotherapeutic effect and potentiates that of Cispatin in 7,12 
dimethylbenzanthracene induced cancer in hamster buccal pouch. 
 
OBJECTIVES:  
The objective of this study was to induce oral squamous cell carcinoma in Syrian 
golden hamsters with 7, 12 dimethylbenzanthracene and to measure the reduction 
in tumour area and gross tumour volume and proliferation of the tumour following 
oral administration of Curcumin, and measure its potentiating action on that of 
parenterally administered Cisplatin. 
 
METHODS: 
A comparative animal study was designed using Syrian golden hamsters. There 
were four study arms with 6 animals each, adding upto 24 animals. 7, 12 
dimethylbenzanthracene was employed as a topical carcinogen, applied to the 
buccal pouch of all 24 hamsters thrice a week for 12 weeks. Following tumour 
induction, the subjects were divided into four groups as follows: 
A – Control group  
B – Curcumin alone group 
C – Cisplatin alone group 
D – Curcumin along with Cisplatin group 
Curcumin was administered enterally at a dosage of 80mg/kg/day for six weeks, 
while Cisplatin was delivered by intraperitoneal injection once a week for four 
weeks, each dose amounting to 40 mg/m2 (body surface area). Following this, the 
animals were sacrificed and the buccal pouch submitted for microscopic analysis. 
The outcomes studied were absolute and percentage reduction in tumour area 
(from pre- to post-intervention), tumour volume post-intervention and proliferative 
index of the tumour based on mib-1 staining on histology. 
 
RESULTS: 
There was 100% tumour incidence in the control arm. The maximum reduction in 
area of tumour was in Group D (77.22%), as compared to 47.82% in Group C and 
16.08% in Group B. The interaction was, thus, synergistic. This difference was 
statistically significant (p value <<<). The lowest tumour volume and lowest 
proliferative index on histology was also observed in Group D, proving that 
maximum tumour inhibition was achieved with combination therapy as opposed to 
either agent alone. 
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INTRODUCTION  
Head and neck squamous cell carcinoma (HNSCC) is among the top three 
cancers in India, with a prevalence of more than 30 %.(1)  The most 
consistently identified risk factor is the abuse of tobacco, both in its smoked and 
smokeless forms.  The magnitude of this cancer is on the rise, and its 
importance as a leading cause of cancer-related death has expanded its scope to 
a global dimension.  In India, oral cancers form the preponderant cancer among 
this group of HNSCC.(2) 
The increasing burden of disease demands prompt diagnosis and early initiation 
of treatment, which is at the same time of standard quality as well as accessible 
and available to the alarming number in need of it. The standard management 
protocol includes radical surgery along with high dose radiochemotherapy. The 
morbidity associated with each of these modalities has been well-documented. 
The problem that is faced in expediting treatment is in fact delayed diagnosis. 
The disease is most commonly an affliction of the lower socioeconomic strata 
of society, and that too predominantly of the rural population in whom tobacco 
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practices run high.  Presentation to a health centre is often delayed, hence 
disease is usually advanced at presentation.  Later the stage of diagnosis, lower 
are the expected treatment outcomes and greater are the costs expected to be 
incurred for more radical multidisciplinary treatment.(3) 
With the new understanding of nutri-therapeutics and application of traditional 
medicine to the treatment of cancer, efforts are underway to arrive at a new 
approach. It is with this regard that we have proceeded to investigate the role of 
turmeric, a time-tested herbal remedy with mysterious therapeutic properties, in 
the carcinogenesis and tumour regression of this particular malignancy. 
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AIMS AND OBJECTIVES 
AIM 
To explore the chemotherapeutic potential of Curcumin ( the active principle in 
Turmeric) in oral cancer models in hamsters. 
OBJECTIVE   
To induce oral squamous cell carcinoma in Syrian golden hamsters with 7,12 
dimethylbenz(a)anthracene  and to measure the reduction in tumour area and 
gross tumour volume,  and to analyse histology and proliferation following oral 
administration of  Curcumin, and measure its potentiating action on that of 
parenterally administered Cisplatin. 
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BACKGROUND AND LITERATURE 
REVIEW 
ORAL CANCER 
Oral cancer is defined as per the International Classification of Diseases scoring 
system, wherein the anatomical boundaries of the oral cavity are described.(4) 
Briefly put, the cancers arising from the lip(ICD 140), mouth and tongue(ICD 
141,143 – 145) fall in this category. The histology of interest is of course, 
squamous cell carcinoma, which forms over 80% of the malignant neoplasms of 
the orofacial region, if facial skin is excluded.(5) 
 
EPIDEMIOLOGY 
On a world wide scale, oral cancer is the tenth highest occurring cancer among 
men and fourteenth among women.(6)  The age-adjusted rates of HNSCC are 
highest in the wine drinking districts of Southern France, followed by Bhutan, 
Bangladesh, India, Brazil and among African Americans in the USA.  Among 
women, the age-adjusted rates are highest in the world in Papua New Guinea 
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and parts of South-Central Asia. (6) In India, the oral cavity is the predominant 
site, whereas in France it is the hypopharynx. (6) This difference in sub-site 
predilection is probably due to variations in exposure to risk factors among the 
population.(6) 
 
Epidemiological studies suggest an increasing trend of incidence of oral 
carcinoma in India. Data was extracted from the Globacon project 2008, and 
crude projections for oral cavity cancer from 2008 to 2030 show an alarming 
increase in incidence of the disease, in both sexes.(6)  The estimated oral-cancer 
related death toll in 2020 in both sexes is almost 70,000.  
 
AETIOLOGY 
More than 75 % of oral cancers are attributable to modifiable risk factors. (7) 
The most prominent among these is tobacco use, both in smoked and smokeless 
forms. Others include excessive alcohol consumption, poor oral hygiene, 
chronic irritation and inflammation induced by ill-fitting dentures or sharp teeth 
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and by chronic infection with Human Papilloma Virus (HPV). Traditionally, 
conditions like syphilitic glossitis and excessive consumption of spicy food are 
also thought to be risk factors. There are also reports of increasing incidence of 
oral squamous cell carcinoma in chronic immunodeficiency states like post-
organ transplantation.(8) 
 
Tobacco:   
Tobacco, whether smoked, chewed or snorted as snuff, has been categorically 
proven to induce carcinogenesis, both as an initiator and as a promoter of 
tumorigenesis. (8) 
 
Alcohol:   
Numerous case-control studies have shown significant association between 
alcohol and risk of oral cancer. (8) The use of alcohol has shown synergistic 
action with the abuse of tobacco. The exact mechanism of action is still unclear 
but numerous hypotheses have been put forward. Alcohol is thought to act as a 
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solvent for carcinogens like those in tobacco. The cytochrome-inducing ability 
of ethanol may accelerate metabolism of carcinogens in the liver and facilitate 
their action.(8)  
 
HPV:  
Chronic infection with HPV, es[ecially strain 16, is an independent risk factor 
for oral cancer, specifically oropharyngeal and tonsillar malignancy. The 
importance of this viral aetiology lies in the fact that in a number of recent 
epidemiological studies, HPV infection has emerged as a leading risk factor 
among young adults afflicted with oral cancer, especially among the non-
smoking population. (7) 
MANAGEMENT 
The main public health challenges involved in confronting this disease include 
lack of reliable screening systems, risk taking behaviour especially among the 
lower socioeconomic groups resulting in increased exposure to known risk 
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factors and delayed diagnosis, lack of education and awareness among the at-
risk population, and prohibitive costs of treatment.  
 
As per the National Comprehensive Cancer Network guidelines(9), the 
treatment algorithm for early oral cancers is single modality, either definitive 
resection or radical radiotherapy. In locally advanced cancers, multidisciplinary 
treatment is the mandate, requiring a combination of surgery, radiotherapy and 
in the presence of high risk factors, chemotherapy. In squamous cell cancers of 
the head and neck, the foremost chemotherapeutic agent, especially for locally 
advanced or unresectable tumours, remains Cisplatin, alone or in combination 
with infusional 5-Flurouracil or Paclitaxel.(10) 
 
 
 
CISPLATIN 
Cisplatin is a platinum based alkylating agent, the first medicine developed in  
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that drug class. Other drugs in this class include carboplatin and oxaliplatin. 
Cisplatin is called the ―penicillin of cancer‖ because it is used so widely and it 
was the first major chemotherapy drug to be developed. Despite the advent of 
targeted therapies to individual cancers, this old drug still retains its relevance in 
treatment protocols for a variety of cancers. In the case of HNSCC, the 
appropriate regimen, whether induction or concurrent chemotherapy, still 
remains a controversy, but studies in both directions have demonstrated benefit 
in advanced malignancy, in the form of decreased incidence of distant 
metastasis and recurrence(10), and definite survival benefit has been 
demonstrated in a few papers. 
The problem with the drug is the side-effect profile which can limit its use. 
These include: 
 Nephrotoxicity  : The nephrotoxicity of platinum-class drugs is a dose-
limiting side effect and seems to be related to reactive oxygen 
species.(11) 
 Neurotoxicity 
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 Nausea and vomiting: This is induced by both a central action on the 
chemotrigger zone as well as a direct action on the intestinal mucosa.  
 Ototoxicity : This is a permanent effect related to its ability to bind to 
melanin in the stria vascularis of the inner ear or the generation of 
reactive oxygen species. It manifests as tinnitus and high frequency 
hearing loss.(11) 
 Dyselectrolytemia: Cisplatin can cause hypomagnesaemia, hypokalaemia 
and hypocalcaemia.(10) 
 Myelotoxicity 
 Haemolytic anaemia: It is suggested that an antibody reacting with a 
cisplatin-red-cell membrane is responsible for haemolysis. 
While modern medicine has yet to provide a completely suitable safer 
alternative for this drug in oral cavity cancers, where can we turn to for one? 
Back to the ―roots‖ of Pharmacotherapy perhaps. 
 
 
15 
 
NUTRICEUTICALS 
―Let food be thy medicine and medicine be thy food.‖ 
                                                                                Hippocrates. 
Hippocrates said it right when he made this famous statement centuries ago. 
Little did he know the implications of his words. The application of food-
derived substances to the treatment of diseases and optimisation of lifestyle is a 
vast avenue for study, and one with tremendous potential for research and 
development. From chronic degenerative diseases to erstwhile incurable 
malignancies, nutri-therapeutics, as it is called, could hold the key to the next 
step in management. 
 
Tumourigenesis is a multi-step pathway that involves transformation of a 
normal cell into an autonomous dysregulated proliferative cell with metastatic 
potential.(12) Although the mysterious details of this process at a molecular 
level still form the subject of research today, what we do know is that every step 
of the process involve alteration of cell signalling pathways. Cancer cells have 
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possess certain abilities that normal cells do not: resistance to growth inhibition, 
independent proliferation and limitless replication, immortalization, stimulation 
of angiogenesis and ability to infiltrate and metastasize.(12) Each of these 
abilities is controlled by specific genes and signalling pathways involving a 
number of transduction molecules , thus offering multiple potential targets for 
therapy. Most of modern day anti-neoplastic agents offer single-target action 
and are therefore ineffective in single-handedly preventing or treating cancer. 
Therefore the current philosophy of chemotherapy is to combine several 
monotargeted drugs or provide drugs that target multiple molecules.  
 
Many plant-derived dietary agents, some used for centuries for their medicinal 
properties, have multi-targeting properties. This has fuelled the development of 
a new stream of drug development, called Nutraceuticals.(13) They offer the 
advantage of being less expensive, with fewer side effects and easier 
accessibility.(13) 
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A nutraceutical, coined by Stephen DeFelice in 1989(14), is any substance 
considered to be food or part of a food that provides medical and health 
benefits. The study of these therapeutic agents holds promise for a whole new 
avenue for cancer prevention therapy. Among the broad variety of 
nutraceuticals that have been investigated, we have focussed on one close to 
home: curcumin, the active principle of turmeric. 
 
TURMERIC : INDIA’S SOLID GOLD (15) 
Turmeric (Curcuma longa Linn.; syn.: Curcuma domestica, Curcuma aromatica) 
is a perennial rhizome from the Zingiberaceae family that is widely cultivated in 
the tropical regions of Asia, most extensively in India, and Latin America. 
Synonyms for this herb include Indian saffron, turmeric root, and yellow root. 
The applicable part of turmeric is the root, which is rich in potassium and iron. 
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Figure 1: Turmeric, a perennial rhizome. (From www.turmeric-curcumin.com) 
 
 
Turmeric has been exploited as a medicinal herb for centuries, forming a part of 
the armamentarium of Ayurvedic medicine.  It is an essential spice, forming a 
component of Indian cuisine and has been used for its preservative properties. 
Turmeric contains numerous phytochemicals, including curcumin. It is now 
recognised that it is curcumin that lends the yellow colour to the spice and is 
responsible for its therapeutic properties.(16) 
 
Curcumin was first isolated in 1815 and its chemical structure was identified to 
be diferuloylmethane (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-
3,5-dione) in 1920. It exists as three analogues: curcumin (curcumin I), 
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demethoxycurcumin (curcumin II) and bisdemethoxycurcumin (curcumin III) of 
which curcumin is thought to be the most biologically active.(17)  
 
                                  
Figure 2: Curcumin exists in three forms, of which Curcumin I is the most abundant.( From 
www.turmeric-curcumin.org) 
 
The pharmacokinetics of curcumin are yet to be fully characterised. What is 
known is that curcumin is poorly absorbed orally due to its poor solubility, and 
its high rate of metabolism in the liver and rapid excretion in bile.(18) During 
absorption, it is changed into products which are more polar and accumulate on 
the serosal aspect of the intestine. It is metabolised by glucuronidation to form 
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curcumin glucoronide and curcumin sulphate, and bioreduction to form 
tetrahydrocurcumin, hexahydrocurcumin and hexahydrocurcuminol.(19) 
Metabolites like Tetrahydrocurcumin(THC) also possess anti-inflammatory 
properties but are less potent that the progenitor.(19) It has been proven 
scientifically that this biotransformation takes place in the intestines as well as 
in the liver.(19) This avid intestinal metabolism may also contribute to its poor 
systemic bioavailability when administered enterally. 
                         
Figure 3: Curcumin and its products of bioreduction(19) 
 
When administered orally, upto 75% can be excreted in faeces, whereas the rest 
appears in traces in the urine.(18)  
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The use of turmeric in the treatment of maladies is one known for generations, 
described in the folklore of Indian and Chinese schools of medicine. The list of 
uses include anti-inflammatory, antiseptic, analgesic, anti-malarial and for 
promotion of wound healing.  
 
The basic principle behind its multifaceted utility is hypothesized to be its anti-
inflammatory property. Dysregulated inflammation is now thought to be the key 
step in many a chronic illness and in carcinogenesis itself(20). Studies have 
shown that curcumin targets many inflammatory mediators, critically Tumour 
Necrosis Factor α (TNFα) (19) and Nuclear factor κβ (NFκβ).(21) The 
suppression of activation of NFκβ has in particular been linked to most of its 
anti-inflammatory and in turn anti-neoplastic effects. (Fig4.) 
 
There is a large body of work reflecting the application of curcumin in chronic 
neurodegenerative, cardiovascular and rheumatic disorders, the details of which 
are beyond the scope of this present discussion. The diagram below summarises 
[Type a quote from the document or 
the summary of an interesting point. 
You can position the text box 
anywhere in the document. Use the 
Text Box Tools tab to change the 
formatting of the pull quote text 
box.] 
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the various therapeutic applications of Curcumin (Fig 5). The picture is 
borrowed from Aggarwal, et al.(20)  
 
 
Figure 4: Molecular targets of curcumin : NF-kB, nuclear factor-kappa B; AP-1, activating protein1; STAT, 
signal transducers and activators of transcription; Nrf-2, nuclear factor 2-related factor; Egr-1, early growth 
response gene-1; PPAR-c,peroxisome proliferator-activated receptor-gamma; CBP, CREB-binding protein; 
EpRE; CTGF, connective tissue growth factor; EGF, epidermal growth factor; EGFRK, epidermal growth factor 
receptor-kinase; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; NGF, nerve growth factor; 
PDGF, platelet-derived growth factor; TGF-b1, transforming growth factor-b1; VEGF, vascular endothelial 
growth factor; AR, androgen receptor; Arh-R, aryl hydrocarbon receptor; DR-5, death receptor-5; EGF-R, 
epidermal growth factor-receptor; EPC-R, endothelial protein C-receptor; ER-a, estrogen receptor-alpha; Fas-R, 
Fas receptor; H2-R, histamine (2)-receptor; InsP3-R, inositol 1,4,5-triphosphate receptor; IR, integrin receptor; 
IL-8-R, interleukin 8-receptor; LDL-R, low density lipoprotein–receptor; MMP, matrix metalloproteinase; 
TIMP, tissue inhibitor of metalloproteinase-3; iNOS, inducible nitric oxide oxidase; COX-2, cyclooxygenase-2; 
LOX, lipoxygenase; Gcl, glutamate-cysteine ligase; NAT, arylamine N-acetyltransferases; IAP, inhibitory 
apoptosis protein; HSP-70, heat-shock protein 70; TNF-a, tumor necrosis factor alpha; IL, interleukin; MCP, 
23 
 
monocyte chemoattractant protein; MIF, migration inhibition protein; MIP, macrophage inflammatory protein; 
ERK, extracellular receptor kinase; IARK, IL-1 receptor-associated kinase; cAK, autophosphorylation-activated 
protein kinase; CDPK, Ca2+-dependent protein kinase; cPK, protamine kinase; JAK, janus kinase; JNK, c-jun 
N-terminal kinase; MAPK, mitogen-activated protein kinase; TK, protein tyrosine kinase; FAK, focal adhesion 
kinase; PhK, phosphorylase kinase; pp60c-src, pp60c-src tyrosine kinase; PKA, protein kinase A; PKB, protein 
kinase B; PKC, protein kinase C; FPTase, farnesyl protein transferase; GST, glutathione S-transferase; HO, 
hemeoxygenase; ICAM-1, intracellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; 
ELAM-1, endothelial leukocyte adhesion molecule-1; SHP-2, Src homology 2 domain-containing tyrosine 
phosphatase 2, uPA, urokinase-type plasminogen activator.(20) 
 
 
 
Figure 5 Curcumin and its application in various pro--inflammatory conditions(20) 
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CURCUMIN AND CANCER  
There have been more than 800 in vitro and in vivo studies demonstrating the 
anti-cancer potential of curcumin(20,22). Every step of the tumourigenesis 
pathway, i.e. tumour initiation, progression, angiogenesis and evasion of cell 
death have been shown to be targeted and downregulated by curcumin through 
various molecular targets including transcription factors, growth factors, 
receptors thereof, cytokines, enzymes and genes regulating cell proliferation 
and apoptosis. The pro-apoptotic property of curcumin is both a direct action as 
well as through signalling pathways involving the above mentioned molecule. 
The specific molecular targets involved are outlined below in Fig 6.(22) 
Because of numerous mechanisms used by curcumin, it is possible that cells 
may not develop resistance to curcumin-induced cell death. 
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Figure 6: Modulation of various cell death pathways by curcumin. Targets up-regulated by curcumin 
are in a blue box, those down-regulated are in a yellow box, and those unaffected are in a white box. 
AP-1 activator protein-1, AMPK 5' adenosine monophosphate-activated protein kinase, BID BH3 
interacting domain death agonist, BIM BCL2-like 11 (apoptosis facilitator), cFLIP cellular FLICE-
like inhibitory protein, FADD Fas-associated protein with Death Domain, DR4 death receptor 
4, DR5 death receptor 5, EGFR epithelial growth factor receptor, IAP inhibitor of apoptosis 
protein, IL-6 interleukin-6, JNK c-Jun N-terminal kinase, mTOR mammalian target of rapamycin, NF-
kB nuclear factor-kB, PI3Kphosphoinositide 3-kinase, STAT3 signal transducer and activator of 
transcription 3, XIAP X-linked IAP (22) 
 
On normal cells, curcumin has found to have minimal if no effect.(22) It is 
thought that normal cells have less absorptive capacity to curcumin as compared 
to tumour cells. Glutathione levels in cancer cells are lower than those in normal 
cells and this has found to increase their susceptibility to curcumin. As alluded 
to earlier, NF-κβ, a main molecular target of curcumin is expressed 
constitutively in cancer cells, but not in normal cells. By suppressing the NF-κβ-
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regulated products, curcumin can modulate tumour cell proliferation and 
survival while not affecting normal cells devoid of this molecule. Some studies 
have demonstrated isolated actions of curcumin on normal cell lines. Human 
epidermal keratinocytes treated with curcumin have demonstrated apoptosis, 
through the inhibition of Activator Protein-1. (23) Curcumin in low 
concentrations decreases the rate of lipid peroxidation and cytochrome c release 
in human hepatocytes and is therefore cytoprotective. However in higher 
concentrations, studies have reported glutathione depletion, activation of 
caspases and direct hepatotoxicity. Increased apoptotic rates have been shown 
in fibroblasts, endothelial cells, human retinal endothelial cells and 
lymphocytes. While all these have been demonstrated in laboratory settings, 
Phase I and II human studies have demonstrated good tolerability with minimal 
side effects(24). This ability to kill cancer cells preferentially to normal cells 
makes curcumin an attractive candidate for anti-cancer drug development. 
 
A detailed review of the application of curcumin to human cancers is perhaps 
beyond the scope of our present discussion.  It has been studied in the 
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management of numerous pathologies, as diagrammatically represented in 
Fig7(20). Curcumin has been shown to exhibit chemopreventive and 
chemotherapeutic potential against variety of different cancers including 
gastrointestinal cancers, genitourinary cancers, melanoma, neurological cancers, 
leukemia and lymphoma; breast cancer, ovarian cancer, head and neck 
squamous cell carcinoma, lung cancer and sarcoma.  
 
Figure 7: Various cancers against which curcumin has found to have therapeutic potential.(20) 
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Curcumin has also been exploited in the control of various treatment and 
disease related symptoms.(20) These include depression, malaise, neuropathic 
pain, anorexia and insomnia. Most of these symptoms are related to disruption 
of cytokine homeostasis secondary to chemotherapy. This has been 
demonstrated in animal experiments where disturbances in levels of pro-
inflammatory cytokines like TNFα, IL-1 and IL-6 paralleled changes in 
―sickness behaviour‖(25) like weight loss, loss of appetite and disturbed sleep 
rhythms. Since curcumin is known to target and down-regulate these 
inflammatory mediators, it has been tried as an ancilliary treatment to palliate 
these symptoms. 
 
CURCUMIN IN ORAL CANCER 
Curcumin has been shown to inhibit the formation and growth of oral cancer 
cell lines in vitro.(26, 27)  Numerous in vivo studies using oral cancer models in 
rats and hamsters have also revealed the efficacy of curcumin, mainly as a 
chemopreventive agent. In one particular study by Manorahan et al(28), the 
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chemopreventive effect of curcumin was studied in induced squamous cell 
cancers of the buccal pouch in hamsters, along with that of piperine. Oral 
squamous cell carcinoma was induced in hamsters by painting the cheek with a 
known carcinogen, 0.5% 7,12 dimethyl benzanthracene three times a week for 
14 weeks. The animals had been randomized as to receving no concurrent 
treatment with curcumin or piperine, or treated alone with each. The total 
number of tumours was determined macroscopically and the buccal pouch was 
also assessed microscopically. While they observed 100 % tumour formation in 
the control arm, the formation of tumour was completely prevented in the 
groups treated with curcumin, as well as with piperine. 
 
A few studies have also assessed the chemotherapeutic effect on oral cancer, 
both on cell lines in vitro models as well as in vivo.(29,30) One such study (31) 
demonstrated the effect of topical curcumin in oral mucosal tumours induced in 
hamsters. The number and volume of visible lesions reduced by almost 40% 
and 60%, respectively. Tumour angiogenesis was also inhibited, along with 
decrease in proliferative index and dysplasia. 
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There are few trials that have tried the drug in human beings for oral cancer. In 
a Phase I clinical trial on high risk premalignant lesions,(29) 7 patients with oral 
leucoplakia were treated with serially incremented doses of curcumin for 3 
months. The maximum tolerable dose was found to be 8g/day. 2 out of the 7 
patients showed significant histological improvement.  
 
CURCUMIN : A CHEMO-RADIOTHERAPY 
SENSITISER 
In addition to its evident anticancer activity both in prevention and therapy,  
curcumin has also been postulated to offer a chemosensitising and 
radiosensitising role in the treatment of malignancy.  In the age of targeted 
therapies and danger of resistance among cancer cells, curcumin may offer a 
way out: a mulitargeted therapy with minimum toxicity and with an ability to 
increase apoptotic rates to standard chemoradiotherapy regimens and thereby 
reduce generation of resistant cancer cell lines. In a review by Goel and 
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Aggarwal (32), they analysed both in vitro and in vivo studies assessing this 
ability of curcumin in a variety of cancers.   
 
In the realm of oral squamous cell cancer however they have mentioned a study 
by Khafif et al(33). Squamous carcinoma cell lines were pre-treated with 
curcumin, and then subjected to doses of radiation. This resulted in significantly 
decreased cell growth and reduced ability for subsequent tumour colony 
formation in response to ionizing radiation therapy. In a more recent 
experiment,(34) the synergistic effect of curcumin and irradiation was 
demonstrated in a similar in vitro setting. 
 
In an experiment by Duarte et al (35) the additive effect of curcumin along with 
Cisplatin was studied using two squamous carcinoma cell lines CAL27 and UM-
SCC1. The study encompassed an in vitro analysis of suppression of tumour cell 
proliferation as well as an in vivo study using the same cell lines xenografted 
onto nude mice. Intravenous tail vein injection of liposomal curcumin and 
intraperitoneal Cisplatin were administered alone or in combination to the mice 
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growing the clinically evident tumours. They were able to demonstrate a greater 
tumour suppression with the combination as compared to either agent alone, in 
both in vitro and in vivo. But their results were not statistically significant in the 
xenograft model. 
 
Suh, et al (36) performed an experiment with similar methodology, in which a 
30% reduction in tumour size was demonstrated with a combination of cisplatn 
and curcumin, a value with statistical significance when compared to the control 
and with each agent alone. 
 
CURCUMIN AS A CHEMO-RADIOPROTECTOR 
Inhibition of pro-inflammatory mediators like NFκβ and suppressing the 
translation of their target genes is the principle mechanism of most 
chemotherapeutic agents. However there action on normal cells in addition to 
cancerous ones is the cause for drug-related toxicity.  
The main limitation of cisplatin, as mentioned earlier is the dose-dependent 
nephro-toxicity, among other crippling side-effects. Reports have shown that 
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cisplatin-induced renal failure may be due to oxidative stress and could 
represent a pro-inflammatory reaction to the drug.(32)  Curcumin, by way of its 
potent anti-inflammatory action, has been studied as a potential tool to alleviate 
the renal damage caused by cisplatin.  
Kuhad. et al  published an animal experiment in which they replicated cisplatin-
induced renal tubular injury and studied the effect of curcumin. They noted that 
not only did curcumin improve subsequent renal function, but also reversed 
signs of oxidative stress like lipid peroxidation and decreased levels of 
inflammatory mediators in the renal tissue.(37) 
There is also evidence to suggest a similar protective role following 
radiotherapy. Numerous in vitro and in vivo studies (37) have demonstrated that 
curcumin protects from radiation induced DNA damage in human intestinal 
cells, blood cells as well as reduces the incidence of pulmonary and cardiac 
toxicity secondary to whole body irradiation. The negative effect of radiation on 
wound healing has also been tackled with curcumin. Treatment with curcumin 
prior to irradiation improved rates of wound contraction, hastened the process of 
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complete wound healing and also reduced the rate of radiation-induced skin 
damage.  
 
HAMSTER MODEL FOR ORAL CANCER 
The most extensively studied in vivo model for oral cancer has been with 
hamsters.  Hamsters have been thought to be the ideal oral cancer model 
because anatomically they possess a large buccal pouch which offers an 
accessible relatively large surface area for study. Furthermore,  oral ancer when 
induced in the hamser cheek model, the resultant tumour was sufficiently 
similar, both histologically as well as behaviourally, to human cancers to justify 
scientific investigation of the same.  Therefore the results are often extrapolated 
relatively accurately to the human scenario. 
 
The most commonly used animals are Syrian Golden Hamsters (Mesocricetus 
auratus). These animals average a life span of two to three years. Adults are 
from 13- 18 cm long and are predominantly nocturnal in habit.(38) They, like 
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most members of the hamster subfamily possess an expandable cheek pouch 
that extends from the cheek to the shoulder. 
 
CARCINOGENESIS : REPLICATING THE 
PATHOLOGY  
Carcinogenesis or oncogenesis is the process of transformation of a normal cell 
into a cancer cell. At a cellular level, the process involves a molecular 
reprogramming, which ultimately results in loss of regulated cell division, 
uncontrolled proliferation, preferential consumption of resources, transgression 
of neighbouring cellular structures and ultimately distant spread. The normal 
process of cell division is tightly regulated be a number of genes, collectively 
known as tumour suppressor genes, and in order to maintain homeostasis this is 
finely balanced with the process of cell death or apoptosis, which is in turn 
regulated by another set of pro- and anti-apoptotic genes. Natural mechanisms 
are in play to repair any flaws that are bound to occur in such a precariously 
balanced system. So the process of cancer generation involves accumulation of 
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mutations at all these various levels i.e tumour suppressor gene inactivation, 
alteration of apoptotic genes and dysfunction of DNA repair genes.(39) Tumour 
promoting areas of the genome i.e protooncogenes, which are in a normal sate 
of dormancy are in turn activated in a domino fashion. The result is the 
evolution of autonomous rapidly dividing cellular clones, capable of 
uncontrolled replication and that are virtually immortal. By the theory of natural 
selection, these cells survive in preference to normal ones, and do so at their 
expense.     
There are many ways to study the process of carcinogenesis, to replicate it for 
the trial of therapies and to evolve preventive strategies. One method of 
induction of cancers spontaneously by the use of chemical treatments, genetic 
alterations or exposure to environmental factors. This offers the advantage of 
providing a comparable living environment as in humans, so that researchers 
may better understand the basis of cancer formation, the influence of the native 
tissue reaction if any, and through the same means highlight any differences 
between the animal and human phenotype.(40) 
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The other method is by culturing known cell lineages of different types of 
cancer in an in vitro method and then inoculating the cells onto a host animal, 
where they may take root and grow, akin to a parasite. The fundamental 
difference between the two methods is that in the latter cancerous cells are 
generated a in a controlled environment and are likely to be monoclonal, each 
identical to the next and all similar points in the pathway of oncogenesis.  
 
 For the purpose of scientific enquiry into carcinogenesis and treatment thereof, 
numerous synthetic carcinogenic agents have been employed.  The one such 
agent that we have utilised for this study is 7,12 dimethylbenzanthracene (7-12 
DMBA).  Dimethylbenzanthracene is a polycyclic aromatic hydrocarbon and is 
one of the most ubiquitous toxic environmental carcinogen.(41) It is lipid-
soluble and is concentrated in biological membranes. It  has been widely used as 
a laboratory carcinogenic agent for the synthesis of cancers of oral mucosa, 
mammary tissue, intestinal mucosa and skin to name a few. 
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7,12 DMBA is oxidised by P450 enzymes and the metabolites thus formed, 
react with DNA to form covalent adducts and depurinated abasic sites within 
the DNA molecule. These acts as tumour initators, and instigate the process of 
tumour formation.(42) 
 
Its use in oral squamous cell cancer has been documented in many studies. 
Specifically in hamster buccal pouch models, its application in a standardised 
regimen over 12-14 weeks (thrice-a-week) has documented 100% tumour 
formation in control arm (28).  Histologically the spectrum of tumour formation 
extends from papillomas, dysplasia, in situ carcinoma and invasive carcinoma, 
thus replicating the multi-step carcinogenetic process in human squamous cell 
carcinoma(28). This offers a definite advantage to in vitro studies or xenograft 
studies with cancer cell culture lines in which homogenous carcinoma cells at 
identical points in the carcinogenetic pathway are analysed.  
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As a potent carcinogen, its use demands utmost in safety precautions on the part 
of the investigator. Recommendations call for the use of a laboratory coat, 
standard nitrile or latex gloves, safety glasses and use of N-100 respirator or a 
fume-hood.(44) 
 
THE NEXT STEP 
At this point, having established to therapeutic and chemosensitizing role of 
curcumin in oral cancer, we propose to apply this to native oral cancer induced 
chemically in the buccal pouch of Syrian Golden hamsters. 
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MATERIALS AND METHODS 
A comparative animal study was designed using Syrian Golden hamsters. In 
consultation with the Clinical Epidemiology Unit of Christian Medical College, 
Vellore and numerous veterans of animal study experts, a sample size was 
arrived at which provided for six animals per study arm.  
 
After drafting the study proposal, it was approved by the Institutional Review 
Board of Christian Medical College, Vellore. Subsequently, the proposal was 
put forward to the Institutional Animal Ethics Committee, where it was 
approved and the use of Syrian Golden hamsters sanctioned.  
 
24 Syrian golden hamsters, between 4-6 weeks of age, were procured from the 
National Institute of Nutrition, Hyderabad. All animals were chosen as male, 
with weight ranging from 80-120 g. They were housed in the Animal Lab at the 
Williams’ building of the Christian Medical College Hospital campus. After an 
acclimatisation period of six weeks the study was commenced. The veterinary 
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staff was employed for the upkeep and feeding of the animals. They were 
nourished with standard issue rodent feed and housed in cages of three each.  
 
The carcinogen of choice, 7, 12 DMBA was purchased from Sigma Aldrich 
India, along with curcumin and protective equipment. The chemical was 
procured in solution form, mixed in methanol. The solution was stored at room 
temperature within a secured area of the Animal facility. Cisplatin was procured 
from the hospital pharmacy. 
 
CANCER INDUCTION PHASE: 
100µL 0.5% 7-12 DMBA solution was painted onto the left buccal pouch of the 
24 hamsters using a No 1 paintbrush. No sedation was required for this 
procedure. Feeds and water were withheld for half an hour to prevent washing 
away of the chemical from the mucosal surface. This was repeated three times a 
week for a total of 12 weeks. At the end of this period the animals were divided  
43 
 
into four groups as follows: 
A – Control group  
B – Curcumin alone group 
C – Cisplatin alone group 
D – Curcumin along with Cisplatin group 
The four groups of six animals each were housed in separate cages for 
identification.  
 
At the end of Induction the tumour number (N0) was counted and gross tumour 
area (A0) was assessed by multiplying the values of the two longest mutually 
perpendicular diameters. Diameters were in turn measured with a linen string 
and a measuring scale as callipers were difficult to negotiate into the rodent oral 
cavity. 
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INTERVENTION PHASE: 
Group A: Group A animals received no further intervention and served as 
controls. 
Group B:  Group B animals received 80 mg/kg of curcumin daily, admixed in 
10 mL of drinking water. The formula was administered by a dropper, 
delivering the appropriate volume of the fluid.  This was continued for six 
weeks. 
Group C: Group C animals were administered 40mg/m2 body surface area of 
commercially available cisplatin, via an intraperitoneal injection. This was 
administered once a week for four weeks. 
Group D: Group D animals received a combination of the above outlined 
regimens. 
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END OF STUDY PERIOD: 
Allowing for one week after the last intervention in each arm i.e.; week 5 for 
Group A and C and week 7 for Groups B and D, the hamsters were sacrificed 
by thiopentone overdose, under the supervision of the Institutional veterinary 
personnel. The left buccal pouch was excised in toto till the depth of the 
underlying muscle.   
 
PATHOLOGICAL EXAMINATION                                                                 
The specimens thus harvested were fixed in 10% formalin and processed and 
imbedded with paraffin. 2-3 micrometer sections were cut, mounted onto slides 
and stained with haematoxylin and eosin for pathologic examination. Additional 
tests performed included staining with mib1 antibody as a marker for 
proliferation. 
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The following were the indicators studied as indicators of degree of 
malignancy: 
1. Gross tumour volume (V): This was calculated by assessing the longest 
three mutually perpendicular diameters and applying the formula: V =   
4
3
𝜋
𝐷1
2
𝐷2
2
𝐷3
2
, where D1, D2 and D3 were the three diameters of the 
tumour. 
2. Gross tumour area (A1): This was calculated by multiplying the tumour 
length and breadth. 
3. Histopathology: The specific type of lesion was identified and reported; 
whether papilloma, dysplasia, in situ carcinoma or invasive carcinoma. 
4. Proliferation index: The number of actively proliferating cells (stained by 
mib-1 antibody) divided by the total number of epithelial cells counted. 
5. Grade: The grade of tumour was designated as 1, for well differentiated 
carcinoma, 2 for moderately differentiated carcinoma, and 3 for poorly 
differentiated carcinoma. 
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PRIMARY AND SECONDARY OUTCOMES: 
Primary outcome assessed was absolute and percentage reduction in tumour 
area and comparative tumour volumes among the four arms. 
Secondary outcomes included degree of suppression of proliferation, assessed 
by comparing proliferative indexes in the post- intervention arms. 
 
STATISTICAL ANALYSIS: 
The absolute reduction in tumour area, percentage reduction in tumour area, 
comparative tumour volumes between the four groups, along  proliferation 
index among these groups were compared by the
 
Kruskal-Wallis test.
 
 
Differences with calculated P values
 
<0.05 were regarded as significant.  
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RESULTS  
Twenty-four hamsters were maintained in our animal laboratory. The average 
weight at the beginning of the study period was 100g. The induction was 
commenced after a six week acclimatisation period.  
 
One animal died at the beginning of the 9th week of induction. The cause of 
death could not be ascertained and the veterinarian felt it could be due to 
improper feeding, perhaps as a result of inadequate acclimatisation. At the end 
of the induction period, the average weight of the surviving 23 animals was 92g. 
 
The tumour incidence and size was recorded and values are displayed in Table 
1. The median tumour area was 315mm
2
 and there were 1.99 tumours per 
animal. 
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The animals were separated into the four groups and housed in specially marked 
cages for the same purpose. Intervention proceeded as detailed earlier. Two 
more animals expired, one during the 13
th
 week and the other during the 14
th
 
week, belonging to group B and group D, respectively. 
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Animal 
Number * 
Diameter1 
(mm) 
Diameter2 
(mm) 
Area of 
tumour 
(mm2) 
Tumour 
Number 
1 15 12 180 1 
3 22 24 528 2 
4 18 23 414 3 
5 12 15 180 1 
6 20 21 420 2 
7 23 25 575 3 
9 11 13 143 1 
10 17 19 323 2 
11 18 20 360 2 
12 15 16 240 2 
13 16 17 272 2 
14 18 20 360 3 
15 21 25 525 4 
16 13 11 143 1 
17 11 13 143 1 
18 12 13 156 1 
19 21 15 315 2 
20 21 23 483 3 
21 21 23 483 3 
22 12 13 156 1 
23 12 10 120 1 
24 14 12 168 1 
 
Table 1: Dimensions and number of tumours induced in the study animals at the end of 
twelve weeks of induction with 7,12dimethylbenzanthracene.  
* Animal number 2 expired prior to the completion of induction, and therefore those values 
have been excluded from further study. 
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Group Animal 
Number 
* 
Diameter 
1 
(mm) 
Diameter 
2 
(mm) 
Diameter 
3 
(mm) 
Tumour 
area 
(mm
2
) 
Tumour 
number 
A 
1 15 12 2 180 1 
3 22 24 3 528 2 
4 18 23 4 41 3 
5 12 15 3 180 1 
6 20 21 4 420 2 
B 
8 21 25 1 525 3 
9 10 12 2 120 1 
10 15 17 2 255 2 
11 17 18 3 306 2 
12 13 15 3 195 2 
C 
13 14 13 1 182 2 
14 15 12 2 180 2 
15 18 20 2 360 4 
16 9 8 2 72 1 
17 8 8 1 64 1 
18 8 9 1 72 1 
D 
19 12 8 1 96 2 
20 11 10 2 110 2 
21 10 9 2 90 2 
22 6 6 1 36 1 
23 5 5 1 25 1 
Table 2: Post intervention diameters including depth of tumour(diameter 3) in mm, followed 
by tumour area(mm2) and tumour number.  
*Animals 2,7 and 24 expired during the study period and hence have been excluded from 
further analysis. 
53 
 
 
 
 
 
 
 
    
Group 
Animal 
number 
Tumour 
Volume 
(mm
3
) 
Proliferative 
index 
(%) 
Grade of 
tumour 
A 
1 188.40 24.11 2 
3 828.96 24.16 2 
4 866.64 22.18 2 
5 282.60 22.00 2 
6 879.20 26.12 2 
B 
8 274.75 22.10 2 
9 125.60 23.50 1 
10 266.90 22.00 2 
11 480.42 20.76 2 
12 306.15 24.88 1 
C 
13 95.25 22.54 2 
14 188.40 21.76 2 
15 376.80 18.18 1 
16 75.36 19.17 2 
17 33.49 19.44 2 
18 37.68 18.29 1 
D 
19 50.24 18.12 1 
20 115.13 18.55 1 
21 94.20 18.94 2 
22 18.84 18.28 2 
23 13.08 18.90 2 
Table 3:  Post intervention tumour volume (mm3), proliferative index and grade of tumour. 
(Grade 1: well differentiated, Grade 2: moderately differentiated, Grade 3: poorly differentiated.) 
54 
 
 
After sacrifice and final histopathological assessment, the results were as 
follows (Table 2 and 3). There was 100% tumour incidence in group A, the 
control arm, proving the carcinogenic potential of 7,12, DMBA.  
 
Among the intervention arms, the reduction in tumour area was expressed as 
absolute decrease in tumour areas i.e. difference between pre-treatment and 
post-treatment values in mm
2 
(Adiff), as well as a percentage of the original area 
(Per-diff).  
 
The results showed a decrease in tumour area in Group B of 54 mm
2
, 87mm
2
 in 
Group C and a decrease of 219mm
2
 in Group D.  The results showed a 16.08% 
decrease in tumour area in animals treated with curcumin alone. In case of 
animals treated with cisplatin alone, this figure was 49.82%, whereas in Group 
D, the combination of curcumin and cisplatin produced a 77.22% reduction in 
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tumour area. The difference between the three groups was found to be 
statistically significant, when analysed with Kruskal Wallis test.  
(p value <<<). 
 
 
 
Similar trends were also observed with median tumour volume. The median 
tumour volume in the control arm was 828.96mm
3
, that of Group B was 274.75 
mm
3
, that in Group C 85.30 mm
3
 and in Group C it was 50.24 mm
3
. The 
difference between the groups was again found to be statistically significant (p 
value 0.005). 
 
   Group Adiff 
(mm
2
) 
PerDiff 
(%) 
Median Tumour 
volume(mm
3) 
Median 
Proliferative 
Index 
A 0 0 828.9600 24.11 
B 54.00 16.0839 274.7500 22.10 
C 87.00 49.8252 85.3033 19.30 
D 219.00 77.2257 50.2400 18.55 
Table 4: Among Groups A, B, C and D, the median reduction in tumour area(Adiff), median 
percentage reduction in tumour area(PerDiff), median tumour volume and Proliferative Index 
are shown. Interquartile range is not mentioned. 
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 Adiff 
(mm
2
) 
PerDiff 
(%) 
Median 
Tumour 
volume(mm
3
) 
Chi-Square 17.695 19.013 12.663 
P value for 
significance 
.001 .000 .005 
 
 
The only reduction in gross tumour number was observed in 3 animals, one in 
Group C and two in Group D. The analysis however was not statistically 
significant. 
Six out of the 21 animals (28.5%) had well differentiated squamous cell 
carcinoma, and the remaining 71.5% had moderately differentiated malignancy. 
The median proliferative indices for the four groups are shown in Table 4. On 
comparing the four group variables using the Kruskal-Wallis test, it was found 
that the difference between the variables was statisticially significant( Chi 
square = 13.384 and p value 0.004).  
Table 5: Using Kruskal-Wallis test for significance the Chi-square and p values for the three 
final outcomes are calculated. All values are statistically significant. 
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The above results are graphically represented below:. 
 
 
 
 
 
 
 Graph 1: A diff - Median tumour area reduction from pre-intervenion to post-intervention, in Groups 
A to D 
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     Graph 2: Per-Diff - median percentage reduction in tumour area from pre-intervention to post-
intervention in Groups A to D 
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Graph 3: Median tumour volume post-intervention in Groups A to D  
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Graph 4: Median Proliferative Index among Groups A to D 
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DISCUSSION 
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DISCUSSION 
Oral squamous cell carcinoma contributes heavily to the cancer burden in India, 
and the world. While the mainstay of therapy remains surgery and radiotherapy 
with chemotherapy for advanced malignancy, long term survival rates remain 
poor, patients suffer from poor quality of life and more often than not patients 
are plagued by high rate of loco-regional as well as systemic recurrence. 
Survival rates in disease with regional spread have remained stagnant at 50 % 
over the past three decades in spite of developments in surgical and adjuvant 
therapy techniques.(45) Now more than ever, there is a need for newer 
strategies. 
 
Increasingly more time and resources are being invested in the application of 
nutri-ceuticals for the management of malignancies. In the field of oral cancer, 
foremost among others is Curcumin. Alone or in combination with the standard 
chemotherapy agents, curcumin emerges as a promising therapeutic modality in 
the treatment of oral SCC.(36) 
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Numerous studies have been reported documenting the chemopreventive as well 
as chemotherapeutic effect of curcumin in oral SCC, some delving into the 
intrinsic molecular mechanisms involved with the same. In a study by Lotempio 
et al (46), the chemotherapeutic potential of curcumin was studied 
simultaneously in an in vitro model using three HNSCC cell lines (one of them 
being oral cavity cancer) along with in vivo xenograft model using athymic 
mice. In the xenograft model, curcumin was administered both as intratumoural 
injection as well as a topical paste. There was a modest reduction in the 
xenograft tumour growth, especially with topical curcumin application, from 
0.08 cc in control arm to just under 0.06 cc in the experimental group, at the end 
of 22 days (25% reduction). 
 
Cisplatin is the standard chemotherapeutic agent for advanced HNSCC, 
including oral cancer.(9) Although its main effect is systemic, to decrease the 
incidence of distant metastasis and hopefully improve long-term survival, it 
64 
 
does possess significant loco-regional action. The chemotherapeutic effect of 
curcumin was compared to cisplatin in a study by  Ellatar and Viriji in 2000. 
(47) Oral cancer cells were developed in vitro and their growth suppression in 
response to curcumin, genistein and quercetin were compared with that of 
cisplatin. Both curcumin and cisplatin effectively suppressed tumour cell 
growth and proliferation in a dose-dependent fashion; however the potency of 
cisplatin in that study was five times that of curcumin.  
 
The chemosensitising action of curcumin in combination with cisplatin for oral 
cancers has been analysed in literature. The study by Duarte, et al (35) has been 
mentioned earlier. With regard to the in vivo experiment, their results showed 
that in comparison to the control, there was a trend towards greater tumour 
inhibition with the curcumin-cisplatin combination (as evidenced by piece-wise 
regression model). However, the estimated difference in slopes of growth were 
not statistically significant (P = 0.1098). (35) 
 
65 
 
The study goes on to demonstrate that the tumour inhibitory function of 
cisplatin is mediated through activation of cellular senescence through p53 and 
p16 modulation. They were also able to show that the same p53 protein 
controlled the activation of NFκβ, a key molecular agent in cancer proliferation. 
As demonstrated by previous authors, the anticancer action of curcumin is 
probably through inhibition of NFκβ activity. The precise mechanism of this 
action was hypothesized as through direct inhibition of the protein Ikappa beta 
kinase (IKKβ). Thus, the chemopotentiation is believed to be due to 
simultaneous, mutually exclusive methods of inhibition of NFκβ transactivation.  
 
Taking this further, Abuzeid et al (48) were able to develop a curcumin 
analogue, called FLLL32, which successfully sensitised cisplatin resistant oral 
SCC cell lines and increased the local action of cisplatin. Lower doses of 
cisplatin could be used to achieve similar oncological outcomes, as compared to 
monotherapy with cisplatin. 
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In the studies mentioned above, all experiments have been performed on 
xenograft tumours, produced by inoculation of cancer cell lines. In fact there is 
no study which assesses the chemopotentiating effect of curcumin on cisplatin 
in a tumour of native buccal mucosa, produced by chemical carcinognenesis.  
The aim of our study was to first replicate an oral cancer model as comparable 
as possible to the natural human one, thereby create a multistep carcinogenetic 
process in the native oral mucosa. It was our hypothesis that such an in vivo 
model would better reflect the natural process as compared to a cell culture in 
vitro or xenograft model. 
 
This was achieved with 7, 12 DMBA. Our induction protocol was based on a 
study by Heber, et al. (43). The authors compared five carcinogenesis protocols 
in the hamster cheek model using 7, 12 DMBA, involving varying periods of 
induction. These were twice-a-week application of the carcinogen for 4 weeks, 
6 weeks, 7 weeks and 8 weeks respectively, and thrice-a-week for 12 weeks. 
Tumour formation was recorded at the end of the study period(T0) in more than 
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90% of animals for the 12 week protocol, one month after T0 in the 8 week 
protocol and at 3, 4 and 8 months after T0 in the 7 week, 6 week and 4 week 
protocols, respectively. This study establishes the 12 week protocol as an ideal 
method for short term follow up of carcinogenesis and experimentation of 
therapeutic modalities. 
 
As earlier authors had demonstrated, in our study 100 % tumour incidence was 
achieved in the animals at the end of the 12 week induction period. This was 
deducted both by gross examination, as well as confirmed by histopathological 
examination of the control arm.  In fact the entire spectrum, from papilloma, 
dysplasia, carcinoma in situ as well as invasive carcinoma was seen. 
 
ANALYSIS OF TUMOUR REGRESSION WITH 
CURCUMIN ALONE. 
In Group B, i.e. the animals who received curcumin as the sole  
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chemotherapeutic agent, there was demonstrable reduction in median tumour 
area from the pre- to post-intervention period. The absolute reduction in area 
was 54 mm
2
, a 16.08 % reduction from the pre-intervention tumour area(A0). 
The median tumour volume in this group was 274.75 mm 
3
 as compared to 
828.96 mm 
3
 in the control group. 
As expected, the therapeutic effect of curcumin alone was far inferior to that of 
cisplatin alone, where the reduction in tumour area was 3 times that of 
curcumin.  
 LoTempio, et al used the topical route for delivery of curcumin, whereas in our 
study, we opted for the enteral route. Much work has been done on determining 
the optimal route of administration of curcumin. Due to its metabolic instability 
and poor solubility in aqueous solvents, its oral bioavailability is limited. Trials 
in humans have demonstrated high daily doses (>8g /day) required in order to 
attain therapeutic systemic levels of curcumin.(24) Higher doses may cause 
side-effects and hence preclude its use. This difficulty has been overcome by 
the conception of innovative methods of drug delivery. Incorporation of 
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curcumin into liposomal structures to enhance delivery has been tried, as in 
studies by Suh et al.(36) Modification of covalent bonding within the curcumin 
structure has led to the development of novel curcumin analogues with better 
solubility and subsequent better bioavailability. In a novel study by Lin, et 
al(49) curcumin was incorporated into lipid based microemulsions and 
administered to the test subjects. The release of the molecules from the 
emulsion was triggered by ultrasonogram signals. This provides the opportunity 
for targeted therapy, wherein the desired action of the drug is effected only at a 
specific site or target organ. 
 
ANALYSIS OF TUMOUR REGRESSION WITH 
CURCUMIN ALONG WITH CISPLATIN. 
Group D, i.e. animals that received combination therapy with curcumin and 
Cisplatin, demonstrated maximum tumour suppression as compared to Cisplatin 
alone. There was a 77.22% reduction in tumour area in this group, with a 
median tumour volume of 50 mm 
3
. This was significantly more suppressive 
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than in group C, where the area of tumour was reduced only by 49.82% and 
tumour volume was 85.30 mm
3
. When analysed for statistical significance of 
differences between the groups, a significant difference was obtained (p 0.005).  
From our analysis we infer that the combination of therapies offers greater 
tumour suppression than either therapy alone. In fact the combination seems to 
be synergistic, with the total area reduction in Group D exceeding the sum of 
reduction of area of Group B and C ( 219 mm
2 
vs 141mm
2
) 
 
 
FUTURE RESEARCH 
It remains uncontested that curcumin is a valuable tool in the fight against oral 
cancer. As more light is being shed on its mysterious mechanisms of action, 
studies have proved its chemotherapeutic and chemopotentiating ability. It will 
be necessary to duplicate results in larger study populations of animals, as well 
as to progress to dose-response studies in animals. The next step would be to 
design experiments focussing on side effect profiling in order to arrive at a 
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suitable formula for combination of these drugs, while achieving the same 
tumour inhibition. 
 
While curcumin may not be conceivable as the single chemotherapeutic agent 
of a regimen for oral squamous cell cancer, the hope is that equal, or possibly 
better, levels of tumour inhibition are obtained with lower doses of Cisplatin 
through combination therapy, as compared to monotherapy with Cisplatin. 
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LIMITATIONS 
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LIMITATIONS 
The main limitation of this study remains the small number of animals 
permissible for study in each group, and thereby the possibility of inaccurate 
extrapolation of the results obtained. There were three cases of mortality among 
the study cases, which again could skew results considerably simply due to the 
small numbers at play. 
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CONCLUSION 
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CONCLUSION 
1. Curcumin inhibits the growth of 7, 12 DMBA induced oral squamous cell 
cancer in hamsters. 
2. Curcumin exhibits highly significant synergistic effect with Cisplatin in 
the inhibition of 7, 12 DMBA induced oral squamous cell cancer in 
hamsters. 
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